• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Myeloid Metaplasia - Pipeline Review, H2 2012 Product Image

Myeloid Metaplasia - Pipeline Review, H2 2012

  • ID: 2298662
  • October 2012
  • 38 pages
  • Global Markets Direct

Myeloid Metaplasia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Myeloid Metaplasia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Myeloid Metaplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myeloid Metaplasia. Myeloid Metaplasia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Myeloid Metaplasia.
- A review of the Myeloid Metaplasia products under development by companies and universities/research READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Myeloid Metaplasia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Myeloid Metaplasia 7
Myeloid Metaplasia Therapeutics under Development by Companies 9
Myeloid Metaplasia Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Myeloid Metaplasia Therapeutics – Products under Development by Companies 13
Myeloid Metaplasia Therapeutics – Products under Investigation by Universities/Institutes 14
Companies Involved in Myeloid Metaplasia Therapeutics Development 15
SuperGen, Inc. 15
Celgene Corporation 16
Myeloid Metaplasia – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
AT-9283 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
dasatinib - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
tipifarnib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Actimid + Prednisone - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
peginterferon alfa-2a - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
zoledronic acid - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
imatinib - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Cyclophosphamide + Prednisone + Thalidomide - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Myeloid Metaplasia Therapeutics – Drug Profile Updates 33
Myeloid Metaplasia Therapeutics – Discontinued Products 35
Myeloid Metaplasia Therapeutics - Dormant Products 36
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38

List of Tables
Number of Products Under Development for Myeloid Metaplasia, H2 2012 7
Products under Development for Myeloid Metaplasia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Early Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
SuperGen, Inc., H2 2012 15
Celgene Corporation, H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 22
Myeloid Metaplasia Therapeutics – Drug Profile Updates 33
Myeloid Metaplasia Therapeutics – Discontinued Products 35
Myeloid Metaplasia Therapeutics – Dormant Products 36

List of Figures
Number of Products under Development for Myeloid Metaplasia, H2 2012 7
Products under Development for Myeloid Metaplasia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Early Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Combination Products, H2 2012 18
Assessment by Route of Administration, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 20
Assessment by Molecule Type, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 22

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos